home > > spring 2002 > ensuring adequate temperature controlled distribution - regulations, recommendations and technology

Ensuring Adequate Temperature Controlled Distribution - Regulations, Recommendations and Technology

New Pharmaceutical Challenges
Temperature controlled deliveries of pharmaceuticals and samples are increasingly common. Five years ago the majority of flu vaccines distributed were not temperature controlled. Today, 65 per cent are delivered through the cold chain using packaging and monitoring advances based on the latest recommendations from regulatory bodies. Collaboration, particularly in research, means sensitive substances need to be shared quickly between partners. However, a number of regulations govern such materials, especially in clinical trials. These regulations are continuing to evolve, but packaging and monitoring technology exists which meets and even anticipates the legal regulations. The following industry issues have led to the need for more advanced temperature controlled packaging, monitoring and supply chains:

Mega-mergers and increasing collaboration - Efforts to achieve a critical mass
in R&D and reduce production and marketing costs have led to companies working
alongside former competitors. The industry as a whole faces greater competition and
more integration with a range of business partners.
Falling R&D productivity and shortening patent times - R&D has become a race
against time where delays can be costly. There are few rewards for second place.
In 2000, 13 of the top 100 drugs sold were not patented. By 2005, 53 of the top 100
drugs will be off-patent when they go to market.
More demanding consumers and end users - Greater availability of information due
to initiatives such as direct-to-consumer marketing has led to more consumer choice and
price competition. This in turn has increased the need for direct distribution to some end
users or more complicated supply chains.
Regulatory changes that demand greater control and accountability.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

By Mario Johnson, Pharmaceutical Industry Development Manager for DHL UK

A Business Studies Graduate from the Buckinghamshire Management College, Mario Johnson is the Pharmaceutical Industry Manager for DHL International (UK) Ltd. Mario joined DHL in 1993 and went on to become a Business Development Manager, first for DHL North East Region, and then for the Central Logistics Department.

In his role as Pharmaceutical Industry Manager, Mario works alongside a team of key account managers and is responsible for developing and implementing state-of-the-art delivery solutions.
Mario Johnson
Print this page
Send to a friend
Privacy statement
News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

Competitive Drive: The Challenges of a Globalised Packaging Industry

Aesica Pharmaceuticals

Packaging is becoming an increasingly competitive and lucrative industry globally. Jeremy Drummond PhD of Aesica Formulated Products looks at the challenges and opportunities this presents.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement